www.Alnylam.com

Contact information

Denise Spinning, Alnylam Business Account Executive
despinning@alnylam.com
904.307.5380

Virtual Exhibit Hall Home

Please see full Important Safety Information for GIVLAARI® (givosiran). For additional information about GIVLAARI, please see full Prescribing Information.

GIVLAARI® (givosiran) Brochure

For U.S. Healthcare Professionals only.

Contact an Alnylam Representative to learn more about GIVLAARI

Since its founding, Alnylam has led the translation of RNA interference (RNAi) into a new class of approved and investigational medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics are a clinically validated approach for the treatment of rare diseases with unmet medical need and prevalent diseases. Alnylam is headquartered in Cambridge, MA. For more information, please visit www.alnylam.com.​